11Mar 2025
DAAs Ensure High Cure Rates in HCV-Infected Children with Comorbidities

DAAs Ensure High Cure Rates in HCV-Infected Children with Comorbidities

Oral direct-acting antivirals (DAAs) demonstrated high efficacy and safety in HCV-infected children, even with comorbidities. A study of 187 children (61% with comorbidities) showed a 98.9% cure rate with sofosbuvir/ledipasvir. Mild side effects like headache and irritability were transient, ensuring uninterrupted treatment.

  • #pediatrics

Like

Save

Share